BNCM Check this box to confirm the Company had no
Post# of 99543
(Total Views: 136)
Posted On: 08/13/2025 8:40:45 PM
BNCM [X] Check this box to confirm the Company had no Convertible Debt issued or outstanding at any point during this period. POST-MERGER PLANS & ACTIVITIES (JULY 2025 ONWARDS)
1. Financial Performance – Delex Pharma posted P293 million ($5.1 million) revenue as of June 2025, up 18.43%
YoY, exceeding the industry average of 8%.
2. Philips Imaging & Hospital Patient Monitors – Finalization of Philips Imaging entitlement moved to Q3/Q4;
appointed Spot Dealer for a new tertiary hospital in Bulacan (P260M contract). Preparing CT & MRI installation
(delivery in 3–4 months). Granted channel partnership for Philips Hospital Patient Monitors; awaiting FDA CMDR
approval (July–Aug 2025).
3. Masimo (USA) Products – Awaiting approvals for Sedline, RAD 7, LiDCO; launch upon first order delivery (est.
P5–P10M revenue in 2025).
4. Portfolio Expansion Under Evaluation – Potential partnerships with Aculife Healthcare, LUYE Lifesciences,
SOLM, Amecath, RTM Healthcare, Innovgas, and KGbio.
5. Oncology Division Growth – Potential partnership with Innokeys (Theracim brand) for Q4 2025; launching
Carboplatin, Leucovorin, and Mesna in Dec 2025.
6. Amsino Receptal Product – First shipment arriving Aug 2025, followed by launch. 7. Pharmacy Expansion – eReseta branches awaiting LTO; expansion aligned with MD Pharma subsidiary.
8. Yuwell Partnership – Launching Glucofit diabetic nutrition and related devices (glucometers, CGMs, BP
monitors, CPAP, BiPAP, nebulizers) in Aug 2025.
9. AGlobal Pharma Partnership – 163 new SKUs for bidding and retail.
10. Pascual Laboratories Partnership – Manufacture/distribute local pharma products for eReseta retail and
bidding.
11. Potential PPPI Partnership – Specialty pharma and device focus, including Philips Imaging.
12. Distribution Expansion – Strategic partnership under negotiation to expand reach, improve collections, and
reduce costs.
13. Provincial Depots & Cebu Office – 9 depots established; Cebu office/warehouse opened to qualify for tenders.
14. New Makati Circuit Satellite Office – Supports CME initiatives near major hospitals.
15. CAPCO Partnership – Awaiting FDA approval for Verathon Glidescope GO 2 (P14.4M potential revenue).
16. Medical Conventions & CME – Continued expansion of the Delex ICU Forum CME program; active participation
in conventions through 2025.
17. Salesforce Restructuring – Transition to generalist model launched July 1, 2025; leadership changes; field
service engineers deployed; training completed in June–July 2025.
18. Retail Expansion Funding – Strategic divestment of legacy brands to finance 60+ retail branches over 3 years.
19. 2026 Strategy Planning – Early planning to begin Aug 2025.
20. DLX Holdings Registration Changes – Ongoing SEC process to register Delex Healthcare Group as parent; no
current BNCM affiliation with DPI until SEC approval.
21. Austerity Measures – Company-wide cost-saving initiatives, including sales territory consolidation (P12.5M
savings), reduced convention participation (P8M savings), hiring freeze, subscription changes, product
rationalization, and HMO switch (P1M savings). https://www.otcmarkets.com/file/company/finan...02/content
1. Financial Performance – Delex Pharma posted P293 million ($5.1 million) revenue as of June 2025, up 18.43%
YoY, exceeding the industry average of 8%.
2. Philips Imaging & Hospital Patient Monitors – Finalization of Philips Imaging entitlement moved to Q3/Q4;
appointed Spot Dealer for a new tertiary hospital in Bulacan (P260M contract). Preparing CT & MRI installation
(delivery in 3–4 months). Granted channel partnership for Philips Hospital Patient Monitors; awaiting FDA CMDR
approval (July–Aug 2025).
3. Masimo (USA) Products – Awaiting approvals for Sedline, RAD 7, LiDCO; launch upon first order delivery (est.
P5–P10M revenue in 2025).
4. Portfolio Expansion Under Evaluation – Potential partnerships with Aculife Healthcare, LUYE Lifesciences,
SOLM, Amecath, RTM Healthcare, Innovgas, and KGbio.
5. Oncology Division Growth – Potential partnership with Innokeys (Theracim brand) for Q4 2025; launching
Carboplatin, Leucovorin, and Mesna in Dec 2025.
6. Amsino Receptal Product – First shipment arriving Aug 2025, followed by launch. 7. Pharmacy Expansion – eReseta branches awaiting LTO; expansion aligned with MD Pharma subsidiary.
8. Yuwell Partnership – Launching Glucofit diabetic nutrition and related devices (glucometers, CGMs, BP
monitors, CPAP, BiPAP, nebulizers) in Aug 2025.
9. AGlobal Pharma Partnership – 163 new SKUs for bidding and retail.
10. Pascual Laboratories Partnership – Manufacture/distribute local pharma products for eReseta retail and
bidding.
11. Potential PPPI Partnership – Specialty pharma and device focus, including Philips Imaging.
12. Distribution Expansion – Strategic partnership under negotiation to expand reach, improve collections, and
reduce costs.
13. Provincial Depots & Cebu Office – 9 depots established; Cebu office/warehouse opened to qualify for tenders.
14. New Makati Circuit Satellite Office – Supports CME initiatives near major hospitals.
15. CAPCO Partnership – Awaiting FDA approval for Verathon Glidescope GO 2 (P14.4M potential revenue).
16. Medical Conventions & CME – Continued expansion of the Delex ICU Forum CME program; active participation
in conventions through 2025.
17. Salesforce Restructuring – Transition to generalist model launched July 1, 2025; leadership changes; field
service engineers deployed; training completed in June–July 2025.
18. Retail Expansion Funding – Strategic divestment of legacy brands to finance 60+ retail branches over 3 years.
19. 2026 Strategy Planning – Early planning to begin Aug 2025.
20. DLX Holdings Registration Changes – Ongoing SEC process to register Delex Healthcare Group as parent; no
current BNCM affiliation with DPI until SEC approval.
21. Austerity Measures – Company-wide cost-saving initiatives, including sales territory consolidation (P12.5M
savings), reduced convention participation (P8M savings), hiring freeze, subscription changes, product
rationalization, and HMO switch (P1M savings). https://www.otcmarkets.com/file/company/finan...02/content
(0)
(0)